Century Therapeutics, Inc. (IPSC) Reports In-Line Q2 EPS

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.38), in-line with the analyst estimate of ($0.38).

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• Leerink Starts Parabilis Medicines (PBLS) at Outperform
• BofA Securities Upgrades T-Mobile (TMUS) to Buy
• William Blair on Glaukos Corporation (GKOS): 'We remain buyers; more so on dips'